Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes.

about

Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer

P2860

Q58719654-1EE7D5C2-64A7-4C9E-AAE4-84CB0B3AA813

P2860

Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes.

Item

http://www.wikidata.org/entity/Q53078543

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Microenvironment-Mediated Mech ...... HER2+ Breast Cancer Subtypes.

@en

Microenvironment-Mediated Mech ...... HER2+ Breast Cancer Subtypes.

@nl

type

Item

label

Microenvironment-Mediated Mech ...... HER2+ Breast Cancer Subtypes.

@en

Microenvironment-Mediated Mech ...... HER2+ Breast Cancer Subtypes.

@nl

prefLabel

Microenvironment-Mediated Mech ...... HER2+ Breast Cancer Subtypes.

@en

Microenvironment-Mediated Mech ...... HER2+ Breast Cancer Subtypes.

@nl

P1476

Microenvironment-Mediated Mech ...... n HER2+ Breast Cancer Subtypes

@en

P2093

Damir Sudar

http://www.w3.org/2001/XMLSchema#string

David Kilburn

http://www.w3.org/2001/XMLSchema#string

Elmar Bucher

http://www.w3.org/2001/XMLSchema#string

James E Korkola

http://www.w3.org/2001/XMLSchema#string

Joe W Gray

http://www.w3.org/2001/XMLSchema#string

Koei Chin

http://www.w3.org/2001/XMLSchema#string

Laura M Heiser

http://www.w3.org/2001/XMLSchema#string

Mark Dane

http://www.w3.org/2001/XMLSchema#string

Michel Nederlof

http://www.w3.org/2001/XMLSchema#string

Moqing Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Targeting androgen receptor in estrogen receptor-negative breast cancer

Improved structure, function and compatibility for CellProfiler: modular high-throughput image analysis software

Comprehensive molecular portraits of human breast tumours

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer.

Fiji: an open-source platform for biological-image analysis.

Repeated observation of breast tumor subtypes in independent gene expression data sets

P304

329-342.e6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CELS.2018.02.001

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Gordon B. Mills

Matthew Whitman

P577

2018-03-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29550255

http://www.w3.org/2001/XMLSchema#string

P932

5927625

http://www.w3.org/2001/XMLSchema#string

Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes.

about

P2860

P2860

Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932